作者
Peter Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, David L DeMets, Olof Bengtsson, Magnus Lindberg, Anna Maria Langkilde, Mikaela Sjöstrand, Bergur V Stefansson, Cecilia Karlsson, Glenn M Chertow, Fan Fan Hou, Ricardo Correa-Rotter, Robert D Toto, David C Wheeler, John JV McMurray, Hiddo JL Heerspink
发表日期
2022/1/1
期刊
The Lancet Diabetes & Endocrinology
卷号
10
期号
1
页码范围
24-34
出版商
Elsevier
简介
Background
Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the DAPA-CKD and DAPA-HF trials.
Methods
This study is a pooled analysis of individual participant data from two phase 3, randomised, double-blind, placebo-controlled, multicentre, clinical trials. Participants with no history of diabetes and HbA1c less than 6·5% (48 mmol/mol) at baseline were included in this pooled analysis. New-onset type 2 diabetes was a prespecified exploratory endpoint in both DAPA-CKD and DAPA-HF trials and is the focus of this analysis. New-onset type 2 diabetes was identified by serial trial measurements of HbA1c (two consecutive values ≥6·5% [≥48 mmol/mol]) or following a clinical diagnosis of diabetes between trial visits. Time to new-onset …
学术搜索中的文章
P Rossing, SE Inzucchi, P Vart, N Jongs, KF Docherty… - The Lancet Diabetes & Endocrinology, 2022